



Accreditation and Designation Statements and Disclosure Report

LUGPA 2026 BPH CME Series

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the Urology Alliance. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live format for this educational activity for a maximum of 3.00 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Live activity date: May 7-21, 2026

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 3.00 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Enduring activity date: June 21, 2026 – June 21, 2029

Financial Disclosures

The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:

| Full Legal Name | Commercial Interest | Role | Level of participation in the activity |
|-----------------|--|-------------------------|--|
| Jason Hafron | Sumitomo Pharma, Dendreon, Photcure, ArteraAI, Astellas, Novartis, Bayer, AstraZeneca, Janssen Biotech, Myriad Genetics, Pfizer, Urogen, Immunis AI, | Consultant | Speaker/Planner/Reviewer |
| | Merck & Co., Inc. | Researcher/Investigator | |
| Thomas Mueller | Calyxo, Teleflex | Consultant | Speaker |
| Ravi Rajan | Astellas, Pfizer | Consultant | Speaker |

| | | | |
|--|--------------------------------|---------------------|--|
| | AstraZeneca, Boston Scientific | Advisor | |
| | Calyxo | Stock/Stock Options | |

“I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies.”

These financial relationships with ineligible companies have been mitigated by PeerPoint Medical Education Institute and LUGPA.

All other presenters, planners, editors, or staff report no relationships to disclose:

“I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies.”

This activity may include discussion of investigational or off-label uses of products or devices. PeerPoint Medical Education Institute does not endorse or promote the use of any product or device outside of its approved indications.